Taken together, these data favor the idea that the anti-TNFR2 antibody-conditioned nanoparticles were able to accumulate in the tumor tissues, and tumor-infiltrating TNFR2-expressing Tregs are a primary cellular target of this treatment. Here, TNFRSF1B is linked to neoplasm.